Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.55 |
| ▸ | HTR2B | P41595 | 5/20 | 0.55 |
| ▸ | DRD1 | P21728 | 4/20 | 0.55 |
| ▸ | HRH1 | P35367 | 4/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | HRH2 | P25021 | 3/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.44 |
| ▸ | HTR1B | P28222 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225398 | 1.00 | HTR2C (0.55) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL3048145 | 1.00 | HTR2C (0.55) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL13701283 | 1.00 | HTR2C (0.55) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL18306406 | 0.87 | HTR2B (0.58) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL27741056 | 0.79 | HTR2B (0.69) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL6989780 | 0.78 | SLC6A2 (0.46) | HTR2CKCNH2SLC6A4HTR7SLC6A2 | |
| SCHEMBL13701284 | 0.78 | HTR2B (0.58) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL4610694 | 0.76 | CHRM2 (0.49) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL4610480 | 0.76 | CHRM2 (0.49) | HTR2CHTR2BDRD1HRH1ADRA1B | |
| SCHEMBL11361173 | 0.76 | HTR2C (0.43) | HTR2CSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-11-24 | — | — | US | claimed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | claimed |
| JP-2010143925-A | METHOD FOR PRODUCING (R)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS HOLDINGS INC | 2010-07-01 | — | — | JP | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTISUB II INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1107753-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS | Advanced Medicine, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999063996-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5HT2 RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CBR1 | HTR2C 1368/4885HTR2B 1563/4885DRD1 74/4885 |
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | HTR2C 1273/4885HTR2B 1312/4885DRD1 40/4885 |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | ADRM1, CYP2E1, OPRD1 | HTR2C 1279/4885HTR2B 1333/4885DRD1 41/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HTR2C 1273/4885HTR2B 1312/4885DRD1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.